Court Speeds Up Apotex Appeal In Amgen Biosimilar Suit
This article was originally published in Scrip
Executive Summary
The US Court of Appeals for the Federal Circuit granted Apotex Inc.'s motion – or at least, in part – for an expedited appeal of a Florida court's decision to impose a preliminary injunction (PI) that prevents the firm from marketing its yet-to-be approved pegfilgrastim biosimilar until 180 days after FDA licenses the product.